Brannagan, Thomas. 2002. Intravenous gammaglobulin (IvIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 59:12 (S33-40)
Guillain-Barre Syndrome Support Group Information Page. Last updated 1997. Accessed April 20, 2003. (http://www.gbs.org.uk/)
Janeway, C., Travers, P. Walport, M., Shlomchik, M. 2001. Immunobiology: The Immune System in Health and Disease. New York, New York: Garland Publishing.
Mahad, DJ, Howell, SJL, Woodroofe, MN. 2002. Expression of chemokines in cervrospinal fluid and serum of patients iwth chronic inflammatory demyelinating polyneuropathy. Journal of Neurosurgery and Psychiatry. 73:320-323
National Institute of Neurological Disorders and Stroke (NINDS).Chronic Inflammatory Demyelinating Polyneuropathy Information Page. Last updated July 1, 2001. Accessed: April 15, 2003. (http://www.ninds.nih.gov/health_and_medical/disorders/cidp.htm)
Ochi, Kazuhide, Kohriyama, Tatsuo, Hagaki, Masahiro, Ikeda, Junko, Harada, Akira, Nakamura, Shigenobu. 2003. Changes in Serum macrophage-related factors in patients with chronic inflammatory demyelinating polyneuropathy caused by intravenous immunolgobulin therapy. Journal of the Neurological Sciences. 208:43-50
van Doorn, Pieter. Chronic Inflammatory Demyelinating Polyneuropathy. Treatment of Nuerological Disorders with Intravenous Immunoglobulins. 2000. London Martin Dunitz Ltd.
Washington Univerisity Neuromuscular Disease Center. last updated February 2, 2003. Acccessed: April 15, 2003. (http://www.neuro.wustl.edu/neuromuscular/antibody/pnimdem.html)
(http://hemato.unice.fr/sanderson/pe.htm) accessed April 25, 2003